IAVI in the News - 2014
IAVI experts have been featured in a variety of prominent news outlets around the world. Below you can access a selection of these articles and opinion pieces, arranged by year of publication.
IAVI Chief Scientific Officer Wayne Koff and others discuss the need for and progress toward an AIDS vaccine, including further exploration of broadly neutralizing antibodies and follow-up research based on the landmark RV144 vaccine candidate (Edition.CNN.com).
Norman Fowler, an IAVI Board member, is “a passionate advocate for people living with HIV/AIDS [who]...took a bold approach as Britain’s Minister of Health to confront the epidemic in the 1980s.” Mark Dodgson of ABC Australia takes a look at some of the lessons from this “unlikely icon’s fearless political career” (ABC.net.au).
IAVI Board Member and former U.K. Cabinet Minister Lord Fowler has called for efforts to ensure homosexuality is decriminalised around the world as part of the fight against HIV / AIDS (PinkNews.co.uk).
The week after the HIV R4P conference highlighted the potential for an array of biomedical measures to control HIV, Anthony Fauci, joined by Margie McGlynn of IAVI and Mitchell Warren of AVAC, explained why only a vaccine will put the “nail in the coffin” of the AIDS epidemic. History supports that commitment, McGlynn added: “What if we had given up on a polio vaccine?” (ScienceSpeaksBlog.org).
HIV R4P: At the inaugural HIV Research for Prevention conference, Prince Bahati of IAVI discussed Africa's ongoing battle with recurrent problems such as "brain drain," a situation which calls for immediate attention in order for the continent to catch up with other developed countries (TheZimMail.co.zw, GlobalPost.com).
Progress toward new HIV prevention tools is taking place “in [an] uncertain funding environment,” say experts recapping the most recent HIV Vaccines & Microbicides Resource Tracking Working Group Report (Blog.GHTCoalition.org).
In papers published in Science and Nature, researchers at and supported by IAVI describe the structure and action of the “spike” on HIV that enables the virus to penetrate CD4 cells. Findings could yield “important clues” for antibody-based vaccines, said IAVI Chief Scientific Officer Wayne Koff (AFP, Reuters, LATimes.com, Weill.Cornell.edu, NIAID.NIH.gov, News.Yale.edu, ScienceDaily.com).
Bill and Melinda Gates, who contributed to IAVI in 2013, are among America’s “top givers” for the year (Forbes.com).
IAVI, the Global Health Technologies Coalition, the Council on Health Research for Development and PATH released a new paper making the case for research and development targeting new and improved health technologies for low- and middle-income countries as part of the post-2015 development agenda (Blog.GHTCoalition.org, GlobalHealth.org).
Poor access to health services is hampering efforts to fight HIV/AIDS in Uganda’s fishing communities, according to experts including IAVI’s Leslie Nielsen (NewVision.co.ug).
A summit in London discussed the extent to which ambitious new targets for treatment scale-up can bring AIDS under control. Speaking in a debate moderated by IAVI Board member Lord Fowler, UNAIDS Executive Director Michel Sidibé said that meeting new “90/90/90” targets would lay the groundwork for ending AIDS as a public health threat by 2030 (UNAIDS.org).
In an interview with a British newspaper, IAVI Board member Lord Fowler backed a campaign to improve sex education in schools, criticizing previous restrictions on discussing homosexuality (London Evening Standard).
Dennis Burton, Director of the IAVI Neutralizing Antibody Consortium and professor at The Scripps Research Institute, is among a select group working on next-generation tools to make an AIDS vaccine a reality (Scripps.edu).
IAVI CEO Margie McGlynn and Immediate Past President of the International AIDS Society, Françoise Barré-Sinoussi, discuss the importance of collaboration between AIDS cure and prevention researchers to eliminate the pandemic once and for all (Project-Syndicate.org).
IAVI Chief Scientific Officer Wayne Koff describes how "[w]ithout a vaccine we will not be able to end the epidemic...Despite all our efforts, we still have a couple of million new infections a year, so we need an effective vaccine" (TheGlobeAndMail.com).
British politician Baroness Gould blogs about her recent visit to IAVI’s Human Immunology Lab in London (LCID.org.uk).
Declining investment could slow research and rollout for new HIV prevention options, according to a new report from IAVI, AVAC and UNAIDS (BioSpectrumAsia.com, Blog.GHTCoalition.org, VaccineNewsDaily, VOANews.com).
AIDS 2014: At the 20th International AIDS Conference in Melbourne, IAVI joined expert partners and advocates to take stock of where we all stand and to individually and collectively step up the pace in the global effort to end HIV/AIDS (AFP, BusinessDayOnline.com, Storify.com).
A photo essay in Germany explores progress with AIDS vaccine R&D in Africa (Morgenpost.de).
New research on HIV transmission shows that viral fitness is an important basis of a “genetic bottleneck” imposed every time a new person is infected (HealthCanal.com).
IAVI works toward an AIDS vaccine that will be effective, affordable and accessible to all who need it, as IAVI Country Director Dr. Rajat Goyal describes in the inflight magazine for SpiceJet (Issuu.com).
Convened by IAVI with support from the Robert Wood Johnson Foundation, a group of 35 experts from the government, academia, industry, and nongovernmental organizations concluded that the ambitious “Human Vaccines Project” was meritorious, timely and potentially transformative (BioResearchOnline.com, VaccineNewsDaily.com).
Research for Development includes efforts with IAVI, the Drugs for Neglected Diseases initiative, the Global Health Technology Coalition and others on the post-2015 development agenda (Research-Europe.com).
NIAID has granted US$13 million to The Scripps Research Institute for Richard Wyatt of the IAVI Neutralizing Antibody Center to lead further work to identify broadly neutralizing antibodies for an HIV vaccine (Scripps.edu, FierceVaccines.com).
IAVI Board member the Rt. Hon. the Lord Fowler describes how ignorance and prejudice impact the fight against HIV, and how the virus “will not be defeated until there is a vaccine.” Lord Fowler’s new book, Aids: Don’t Die of Prejudice, was released in June 2014 (TheGuardian.com, Standard.co.uk, BBC.co.uk, FT.com).
IAVI and partners initiated an early clinical trial of a new strategy to prevent HIV (Nature.com).
Support and media exposure for organizations like IAVI help keep the important role of vaccines in healthcare at the forefront and drive attention toward developing vaccines for diseases that currently have no cure (LifeScienceLeader.com).
IAVI CEO Margie McGlynn applauds the Government of Canada’s continued efforts to push women’s and children’s health and describes why an AIDS vaccine is essential for women (HuffingtonPost.ca).
Co-hosted by IAVI, the Drugs for Neglected Diseases initiative and the Global Health Technologies Coalition, a side event at the World Health Assembly on how research and innovation can achieve health and sustainable development is among several events to look out for in Geneva (Devex.com).
World AIDS Vaccine Day: IAVI President and CEO Margie McGlynn joins UNAIDS and several other partners in commemorating World AIDS Vaccine Day and the quest for a world without AIDS (UNAIDS.org).
Scientists from The Scripps Research Institute and IAVI have discovered a new vulnerable site on HIV that antibodies can attack to prevent infection from a broad range of the virus’ many variants (U-T San Diego, NBC San Diego, FierceBiotechResearch.com, VaccineNewsDaily.com, InstinctMagazine.com, Medical Technology Business Europe, LaStampa.it, Farmacia.it, ABC.es, Monitor.co.ug, DDN-News.com).
Product development partnerships like IAVI continue to channel funding for promising new HIV prevention tools like vaccines, according to a new amfAR issue brief on “Sustaining the Global HIV Response: Innovative Financing Options” (amfAR.org).
“There have been a number of articles recently suggesting that we are near the end of the AIDS epidemic, which is pretty bold and pretty risk to say without a preventive HIV vaccine,” says Gwynn Stevens of IAVI about the value and importance of vaccine R&D (SciDev.net, Thomson Reuters Trust, AllAfrica.com).
International Women's Day 2014: Remarks from IAVI President and CEO Margie McGlynn on the transformative potential of an AIDS vaccine for gender equality featured in USAID IMPACTblog, Kaiser Family Foundation newsletter and The Huffington Post Germany / the German ONE Campaign blog (English translation available here).
IAVI's partnership with Theraclone Sciences represents one of several consortia pushing AIDS vaccine development forward (Xconomy.com).
IAVI Chief Scientific Officer Wayne Koff, IAVI Scientific Advisory Committee Chair Robin Weiss and IAVI Country Director Rajat Goyal discuss the status of AIDS vaccine R&D, including important work being conducted in India (TheHindu.com, BioSpectrum India).
IAVI’s Jill Gilmour discusses promising approaches to fighting HIV, including Dennis Burton’s retrovaccinology work at the Neutralizing Antibody Consortium, among other milestones (Wired.co.uk).
“[I]n the next five years we’re going to see the first [HIV] vaccines coming into clinical testing that might induce neutralizing antibodies, and that’s going to be incredibly exciting,” notes IAVI’s Jill Gilmour (Wired.co.uk).
Scientists at The Scripps Research Institute, with support from IAVI, developed a new method for designing artificial proteins and applied the technology for a candidate vaccine against respiratory syncytial virus (FierceBiotechResearch.com).
Former U.N. Secretary-General says there is no room for complacency when it comes to addressing global health issues like AIDS, which IAVI is helping to combat in its quest for a vaccine (DeccanHerald.com).
In congratulating Dr. Deborah Birx on her nomination as U.S. Global AIDS Coordinator, IAVI President and CEO Margie McGlynn observed: “Dr. Birx is a longtime advocate for a robust and comprehensive global response to HIV and AIDS that includes a vaccine" (VaccineNewsDaily.com).